Transcode Therapeutics, Inc. — Form SCHEDULE 13D/A
Filed July 17, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 18/100
What the filing says
CK Life Sciences Intl (Holdings) Inc filed an amended Schedule 13D/A on 2026-07-17 regarding beneficial ownership in Transcode Therapeutics, Inc. The filing does not disclose the specific ownership percentage, share count, dollar amount, or nature of the amendment in the provided text. No material transaction, price, or ownership change figures are stated.
Why this rating
Amendment to existing 13D disclosure; no material transaction, price, or substantive ownership change disclosed. Routine regulatory filing.
See more from July 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.